Samsung Biologics Valuation
| 207940 Stock | 1,000,000 0.00 0.00% |
At this time, the company appears to be fairly valued. Samsung Biologics has a current Real Value of USD973665.0 per share. The regular price of the company is USD1000000.0. Our model measures the value of Samsung Biologics from inspecting the company fundamentals such as Operating Margin of 0.32 %, return on equity of 0.0751, and Shares Owned By Institutions of 13.80 % as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Samsung Biologics' price fluctuation is very steady at this time. Calculation of the real value of Samsung Biologics is based on 3 months time horizon. Increasing Samsung Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Samsung Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Samsung Stock. However, Samsung Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1000000.0 | Real 973665.0 | Hype 1000000.0 |
The real value of Samsung Stock, also known as its intrinsic value, is the underlying worth of Samsung Biologics Company, which is reflected in its stock price. It is based on Samsung Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Samsung Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Samsung Biologics Co helps investors to forecast how Samsung stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Samsung Biologics more accurately as focusing exclusively on Samsung Biologics' fundamentals will not take into account other important factors: Samsung Biologics Total Value Analysis
Samsung Biologics Co is presently forecasted to have takeover price of 58.92 T with market capitalization of 57.3 T, debt of 1.11 T, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Samsung Biologics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
58.92 T | 57.3 T | 1.11 T |
Samsung Biologics Investor Information
About 75.0% of the company shares are owned by insiders or employees . The company recorded earning per share (EPS) of 2417.83. Samsung Biologics had not issued any dividends in recent years. The entity had 476:471 split on the 28th of February 2022. Based on the key indicators related to Samsung Biologics' liquidity, profitability, solvency, and operating efficiency, Samsung Biologics Co is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Samsung Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Samsung Biologics has an asset utilization ratio of 19.67 percent. This suggests that the Company is making USD0.2 for each dollar of assets. An increasing asset utilization means that Samsung Biologics Co is more efficient with each dollar of assets it utilizes for everyday operations.Samsung Biologics Ownership Allocation
Samsung Biologics shows a total of 71.17 Million outstanding shares. Samsung Biologics has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 75.18 % of Samsung Biologics outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Samsung Biologics Profitability Analysis
The company reported the revenue of 1.57 T. Net Income was 393.59 B with profit before overhead, payroll, taxes, and interest of 723.35 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Samsung Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Samsung Biologics and how it compares across the competition.
About Samsung Biologics Valuation
The stock valuation mechanism determines Samsung Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Samsung Biologics. We calculate exposure to Samsung Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Samsung Biologics's related companies.8 Steps to conduct Samsung Biologics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Samsung Biologics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Samsung Biologics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Samsung Biologics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Samsung Biologics' revenue streams: Identify Samsung Biologics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Samsung Biologics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Samsung Biologics' growth potential: Evaluate Samsung Biologics' management, business model, and growth potential.
- Determine Samsung Biologics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Samsung Biologics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Samsung Stock analysis
When running Samsung Biologics' price analysis, check to measure Samsung Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Samsung Biologics is operating at the current time. Most of Samsung Biologics' value examination focuses on studying past and present price action to predict the probability of Samsung Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Samsung Biologics' price. Additionally, you may evaluate how the addition of Samsung Biologics to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |